Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Massimo Massi Benedetti

Showing results (1-10 of 29) with videos related to

Pageof 3
Sort By:
Current Medical Research and Opinion|August 18, 2006
Changing targets in the treatment of type 2 diabetesMassimo Massi-Benedetti
Clinical Therapeutics|July 11, 2003
Glimepiride in type 2 diabetes mellitus: a review of the worldwide therapeutic experienceMassimo Massi-Benedetti
Diabetes Research and Clinical Practice|March 18, 2014
Discrimination and diabetesMassimo Massi Benedetti
Diabetes Technology & Therapeutics|June 15, 2007
Quality and behavior of glimepiride generics versus amaryl under stressed conditionsGiuseppe Attorrese, Massimo Massi-Benedetti
Diabetes Care|February 15, 2008
Treatment of type 2 diabetes with combined therapy: what are the pros and cons?Massimo Massi-Benedetti, Marco Orsini-Federici
Artificial Cells, Blood Substitutes, and Immobilization Biotechnology|May 20, 2003
The artificial pancreasPaolo Brunetti, Marco Orsini Federici, Massimo Massi Benedetti
Acta Diabetologica|October 13, 2019
An in-depth assessment of diabetes-related lower extremity amputation rates 2000-2013 delivered by twenty-one countries for the data collection 2015 of the Organization for Economic Cooperation and Development (OECD)Fabrizio Carinci, Luigi Uccioli, Massimo Massi Benedetti, et al.
Vascular Health and Risk Management|November 1, 2007
PROactive 07: pioglitazone in the treatment of type 2 diabetes: results of the PROactive studyErland Erdmann, John Dormandy, Robert Wilcox, et al.
Diabetes Care|June 29, 2004
The prospective pioglitazone clinical trial in macrovascular events (PROactive): can pioglitazone reduce cardiovascular events in diabetes? Study design and baseline characteristics of 5238 patientsBernard Charbonnel, John Dormandy, Erland Erdmann, et al.
Treatments in Endocrinology|May 6, 2005
The costs of type 2 diabetes mellitus in Italy: a CODE-2 sub-studyCarlo Lucioni, Maria Paola Garancini, Massimo Massi-Benedetti, et al.
Pageof 3

Showing results (1-10 of 29) with videos related to

Sort By:
Pageof 3
Current Medical Research and Opinion|August 18, 2006
Changing targets in the treatment of type 2 diabetesMassimo Massi-Benedetti
Clinical Therapeutics|July 11, 2003
Glimepiride in type 2 diabetes mellitus: a review of the worldwide therapeutic experienceMassimo Massi-Benedetti
Diabetes Research and Clinical Practice|March 18, 2014
Discrimination and diabetesMassimo Massi Benedetti
Diabetes Technology & Therapeutics|June 15, 2007
Quality and behavior of glimepiride generics versus amaryl under stressed conditionsGiuseppe Attorrese, Massimo Massi-Benedetti
Diabetes Care|February 15, 2008
Treatment of type 2 diabetes with combined therapy: what are the pros and cons?Massimo Massi-Benedetti, Marco Orsini-Federici
Artificial Cells, Blood Substitutes, and Immobilization Biotechnology|May 20, 2003
The artificial pancreasPaolo Brunetti, Marco Orsini Federici, Massimo Massi Benedetti
Acta Diabetologica|October 13, 2019
An in-depth assessment of diabetes-related lower extremity amputation rates 2000-2013 delivered by twenty-one countries for the data collection 2015 of the Organization for Economic Cooperation and Development (OECD)Fabrizio Carinci, Luigi Uccioli, Massimo Massi Benedetti, et al.
Vascular Health and Risk Management|November 1, 2007
PROactive 07: pioglitazone in the treatment of type 2 diabetes: results of the PROactive studyErland Erdmann, John Dormandy, Robert Wilcox, et al.
Diabetes Care|June 29, 2004
The prospective pioglitazone clinical trial in macrovascular events (PROactive): can pioglitazone reduce cardiovascular events in diabetes? Study design and baseline characteristics of 5238 patientsBernard Charbonnel, John Dormandy, Erland Erdmann, et al.
Treatments in Endocrinology|May 6, 2005
The costs of type 2 diabetes mellitus in Italy: a CODE-2 sub-studyCarlo Lucioni, Maria Paola Garancini, Massimo Massi-Benedetti, et al.
Pageof 3